The Companies That Matter Never Win the Product War

Empirical Security

Empirical Security's $25M Series A stands out because it comes from founders who spent years building the math that changed an entire industry before deciding to build the company they believed should have existed all along.

The round, led by Brightmind Partners with returning participation from Costanoa Ventures and Hyde Park Angels, brings Empirical Security's total funding to $37M. It also puts another spotlight on CEO Ed Bellis, Chief Data Scientist Michael Roytman, and Chief Data Scientist Jay Jacobs, whose work has influenced how organizations think about vulnerability management long before Empirical Security was founded.

Cybersecurity has always had an interesting relationship with volume. More alerts, more dashboards, more vulnerability scores, more noise. Along the way, people started confusing more data with better decisions. Turns out those are not roommates. They are barely acquaintances. Empirical Security is taking a different route. The company is not asking organizations to chase every vulnerability. It is asking a much better question: Which vulnerabilities actually matter inside your environment?

That is where the name earns its keep. Empirical is not selling guesses dressed up as confidence. It is rooted in evidence. Its Foundation model analyzes more than 18,000 known exploited CVEs and is trained on roughly 2 million exploitation events. Radiant then layers in what makes every organization unique, including assets, configurations, controls, telemetry, and patching behavior. Same internet. Different reality. That is a much more honest conversation than pretending every enterprise lives in the same neighborhood.

Ed Bellis, Michael Roytman, and Jay Jacobs have seen this movie before. They helped pioneer Risk-Based Vulnerability Management at Kenna Security and played central roles in creating the Exploit Prediction Scoring System. Experience has a funny habit of making overnight success look suspiciously like a decade of homework.

Another detail worth noticing is transparency. Empirical Security says it publishes its own false positive rate. That sounds simple until you realize how rare it is. In an industry where everyone promises certainty, voluntarily measuring your misses says more than another polished product demo ever could.

The business lesson is not hidden between the lines. Founders who solve a painful problem once earn credibility. Founders who keep solving the same problem from first principles earn trust. Investors notice the difference. Markets eventually do too. Security teams do not need another alarm clock screaming at 3 in the morning. They need better judgment at 3 in the afternoon. That distinction may end up being worth far more than the funding announcement itself.

Cascade

Cascade just raised $3.5M to tackle one of construction's biggest competitive advantages: finding the next project before everyone else does. CEO Hannia Zia, CTO Joana Ferreira, and the Cascade team secured backing from Andreessen Horowitz Speedrun, Ada Ventures, Blitzscaling Ventures, Índico Capital Partners, shuckerVC, G2C Ventures, and Snowball VC. The investor syndicate reflects growing conviction that one of the world's largest industries still has enormous room for better intelligence.

Construction has never suffered from a lack of projects. It has suffered from a lack of visibility. Opportunities are scattered across permits, bond filings, government meetings, capital plans, property records, and countless public sources that nobody has the time to stitch together before someone else does. Winning often starts weeks before the bid ever appears.

Cascade figured out that the real blueprint is not poured in concrete. It is built from signals.

The platform predicts upcoming projects before they are publicly announced, matches architecture, engineering, and construction firms with work they are positioned to win, automates proposal writing, and analyzes specifications that can derail a deal before the first shovel ever hits the ground. It also integrates with existing ERP systems while reducing proposal cycles from weeks to days. That means less paperwork and more pursuit.

Even more interesting is the network effect taking shape. Every firm that joins strengthens the system's ability to identify opportunities, connect potential teaming partners, and improve matching accuracy across the AEC ecosystem. That is how software graduates from being a tool to becoming infrastructure.

Customers are already seeing the impact. Cascade says its platform surfaces more than $120M in additional opportunities every month, with clients ranging from Munoz Engineering, Smallwood, FORGE Architecture, and S.A. Casey Construction. One customer credits the platform with uncovering and helping win a $6M project that otherwise would have remained invisible.

Founders earn rounds like this long before the announcement ever arrives. Hannia Zia brought experience scaling Google Pay India to more than 100M users before leading product at UnlikelyAI. Joana Ferreira built machine learning systems at Amazon, Google Search, Freetrade, and later led AI platform development at UnlikelyAI. That combination of product obsession and technical depth usually leaves fingerprints on companies long before investors write checks.

The lesson for every founder is simple. Markets reward people who discover value before everyone else notices it. Cascade is not just helping firms build buildings. It is helping them find tomorrow's skyline while everyone else is still reading yesterday's plans.

Estrigenix Therapeutics

Estrigenix Therapeutics just announced the first closing of a $2M Series Seed financing led by Talents Fund I, and this is one of those biotech rounds that deserves more than a polite skim.

The Milwaukee company is advancing selective estrogen receptor-beta (ERbeta) therapeutics for menopause-related symptoms and neurodegenerative conditions. Translation: this is not another vague women's health pitch stapled to a market-size slide. Estrigenix is taking a specific biological pathway, years of academic research, and a protected IP position, then trying to turn that into drugs that could address hot flashes, cognition, mood, anxiety, and broader neurological health.

That matters because women's health has spent decades being treated like a niche category while affecting massive patient populations. Funny how a market becomes "interesting" once the science gets sharper and the commercial opportunity becomes harder to ignore.

This round will support lead optimization and completion of the company's translational preclinical package ahead of IND-enabling studies. That is not the glamorous part of biotech. It is the hard, necessary part where a company proves whether the biology can keep earning the next milestone.

The team behind the company is also worth watching: CEO Victoria Zellmer, PhD; CSO Karyn Frick, PhD; co-founders Daniel Sem, PhD, MBA, JD, and William Donaldson, PhD; Executive Chair Patricia Scheller; and the broader Estrigenix team. The research foundation traces back to the University of Wisconsin-Milwaukee, Marquette University, and Concordia University Wisconsin, giving the company a genuine academic foundation rather than a borrowed buzzword.

Talents Fund I is backing a company operating in a category that is overdue for sharper science and more serious capital. The broader lesson is simple: neglected markets do not stay neglected forever when credible teams pair differentiated biology with venture-scale ambition.

Another signal is regional. Milwaukee does not need to pretend to be Boston or San Francisco to build serious biotech. When university research, experienced operators, and focused capital align around a real patient problem, geography becomes part of the story rather than a limitation.

Estrigenix Therapeutics, Talents Fund I, and the leadership team are now entering the next phase of that journey. The capital is early, the biology still has to prove itself, and that is exactly why this round is interesting. Biotech is built milestone by milestone, not headline by headline. The signal is not hype. It is focused capital moving toward overlooked biology with a clearer path to company-building.

Sila

Sila just raised $300M in private equity funding, led by Atreides Management and Sutter Hill Ventures, with participation from 8VC, Bessemer Venture Partners, Matrix Partners, and funds and accounts advised by T. Rowe Price Associates. The financing says as much about years of execution as it does the size of the investment. That kind of investor lineup does not gather because of a good pitch deck. It shows up when execution has been stacking receipts for years.

CEO Gene Berdichevsky, CTO Gleb Yushin, VP of Engineering Alex Jacobs, and the Sila team secured backing from a group of investors that reflects growing confidence in the company's long-term execution. Building breakthrough battery materials is difficult. Scaling manufacturing inside the United States while the global supply chain remains heavily concentrated elsewhere is an entirely different challenge.

Sila has been engineering silicon-carbon anodes that push lithium-ion batteries beyond the limits of traditional graphite. Titan Silicon is designed to deliver meaningfully higher energy density while finding its way into products ranging from wearables to electric vehicles, robotics, AI hardware, defense systems, satellites, and beyond. Physics does not care about marketing. It rewards engineering.

This latest investment will support expanding production at the Moses Lake, Washington, facility, where Phase 1 starts at 2 GWh with ambitions reaching as high as 250 GWh over the next five years. That is not simply adding capacity. It is building infrastructure for an industry that increasingly understands domestic manufacturing is becoming a competitive advantage rather than a patriotic talking point.

There is a lesson here for every founder. Investors did not back a concept. They backed years of technical execution, commercial validation, manufacturing discipline, strategic partnerships, and leadership willing to tackle one of the hardest problems in clean technology. That is the part founders should study. The market loves the myth of the sudden breakthrough, but the money usually shows up after the hard work has survived customers, factories, patents, supply chains, and time. Sila is not selling the idea of scale anymore. It is operating within it.

Venture capital follows conviction. Private equity follows proof. The battery conversation has never really been about batteries. It has always been about who controls the future of transportation, AI infrastructure, defense capability, consumer electronics, and the energy systems that connect them all. The companies building those foundations today will not need to tell history they mattered. History has a habit of moving forward on its own.

Photon Queue

Photon Queue just raised an oversubscribed $4M Seed round led by Playground Global, and the story is bigger than another quantum startup securing capital. The company is tackling one of quantum's least forgiving infrastructure problems: making photons wait.

That sounds absurd until you remember what photons do for a living. They move fast, resist interference, and then ruin everyone's day when a system needs them synchronized. Photon Queue is building room-temperature quantum memories that store and synchronize single photons using free-space optical loops, high-reflectivity mirrors, and optical switches. No cryogenics. No elaborate transduction maze. Just practical hardware aimed at one of the constraints quantum computing, networking, and sensing all eventually encounter.

CEO Nathan Arnold, CTO Kelsey Ortiz, and the Photon Queue team secured backing from Playground Global to advance a category where deep tech succeeds only when exceptional science becomes deployable hardware. Deep tech does not become a company because the science is impressive. It becomes a company when the team turns lab work into something customers can deploy, manufacturers can scale, and investors can underwrite.

Photon Queue already has more than a thesis. Sandia National Laboratories and the University of Maryland are using the company's quantum memory systems in environments where interesting research is not enough. The hardware has to perform. It has to integrate. It has to make the future less theoretical.

The company's roots at the University of Illinois Urbana-Champaign matter as well. Photon Queue grew from research connected to Professor Paul Kwiat's lab before moving toward commercialization through the kind of founder translation that separates papers from products. That is where Nathan Arnold and Kelsey Ortiz deserve attention. The job is not just understanding the science. It is making the market understand why the science matters now.

Playground Global's investment is equally noteworthy. Every major technology wave eventually discovers the unglamorous layer that determines whether the entire ecosystem scales. AI needed chips. Cloud needed data centers. Electric vehicles needed charging networks. Quantum will need memory, synchronization, networking, and manufacturing discipline.

Photon Queue is not trying to be the loudest company in quantum. It is building the equipment everyone else may need before the industry can truly scale. That is usually where the most interesting companies hide.

Vikk AI

Legal tech has spent decades teaching people one lesson: if you need legal help, good luck figuring out where to start. Endless directories, confusing jargon, and enough billboards to make you think every attorney specializes in everything. It was only a matter of time before AI showed up and asked a pretty uncomfortable question. What if finding legal guidance became as natural as asking a question instead of knowing where to ask it? That question just attracted $4.2M in conviction.

CEO Walid Romaya, CTO Haytham Allos, CLO Tabrez Ebrahim, and the Vikk AI team secured $4.2M across a $700K pre-seed round and a $3.5M seed round. The company also attracted support from strategic angel investors including Ronson Shamoun, Joe Samo, Brad Jowell, Cooper Collins of MagnaSci Ventures, and additional investors who recognized the opportunity early.

Vikk AI isn't trying to replace attorneys. That would be a terrible business model and an even worse dinner conversation. The company is building an AI-powered legal discovery platform that helps consumers understand legal questions, analyze documents, generate basic legal paperwork, and connect with the right attorney based on practice area and location. That's a meaningful distinction because access is often the biggest obstacle, not expertise.

The timing makes this raise even more interesting. Vertical AI is separating itself from generic AI in a big way. Winning isn't about having another chatbot. It's about owning the workflow, understanding the language of an industry, and creating an experience that feels purpose-built instead of bolted together. Law is one of those industries where context isn't optional. It's everything.

Another signal worth paying attention to is Vikk AI's selection for the AWS and Meta Build with Llama program. Being chosen from more than 1,000 applicants, along with receiving AWS infrastructure support and promotional credits, tells you experienced technical organizations believe the platform is solving a real problem with meaningful technical depth.

There are business lessons buried inside this funding round. Investors continue rewarding founders who attack highly specialized markets with focused AI products instead of broad promises. Distribution matters just as much as the technology itself. When you create value for multiple stakeholders, consumers seeking answers, attorneys looking for qualified clients, and enterprises searching for legal intelligence, you build a business with far more leverage than a single-feature application.

Legal services aren't getting less complex. Expectations around access, speed, and simplicity are changing anyway. Companies that can remove friction without removing professional expertise are building exactly where the market is headed. That's why this round deserves attention. It's not just capital moving. It's another reminder that the next generation of AI winners will be measured by the industries they deeply understand, not the buzzwords they can string together.

MyDecisive

MyDecisive emerged from stealth with $12M in seed funding led by Copper Sky Capital, taking aim at one of enterprise software's most expensive problems: telemetry waste. Most companies collect telemetry like they're hoarding old gym memberships. They keep paying for data they'll never use, then wonder why observability feels more expensive than clarity. We built machines to tell us what's happening, then buried ourselves under so much noise that the signal started filing complaints. That is why MyDecisive is worth watching.

CEO Ari Zilka and the MyDecisive team secured backing from Copper Sky Capital to build around SmartHub and Octant. Zilka has spent decades tackling the hard parts of infrastructure, from Terracotta and Ehcache to Walmart.com, Hortonworks, and New Relic. That background matters because production systems do not care about optimism. They care about whether the software still works when the dashboard is screaming and the invoice keeps climbing.

MyDecisive is attacking observability from a different angle. Instead of accepting that every byte of telemetry deserves a permanent home and another bill, SmartHub filters OpenTelemetry and Kubernetes data on the wire, reducing waste while preserving the events that matter. Octant then layers in governance, automation, security, and AI-driven operational workflows so teams can move from watching infrastructure to actively managing it. That distinction is bigger than it sounds.

Enterprise AI has been obsessed with bigger models, faster chips, and more compute. Meanwhile, someone still has to manage the flood of operational data those systems generate. Ignore that reality and costs quietly compound until finance starts asking questions nobody wants to answer.

Open standards continue to create leverage. MyDecisive built around technologies enterprises already trust, including OpenTelemetry and Kubernetes, instead of asking buyers to rip everything apart and start over. Founders love talking about disruption. Enterprise buyers usually prefer evolution that does not create another migration headache.

The $12M will support product development and go-to-market expansion across finance, retail, telecom, and healthcare. Those industries do not reward clever demos. They reward reliability, governance, automation, and infrastructure that keeps working when everyone else is asleep.

The company name is MyDecisive, but the real takeaway is that decisive companies solve expensive problems customers already know they have. Everything else is just another dashboard waiting for someone to ignore it.

Gritt

Gritt just raised a $26M Series A led by Obvious Ventures, and the financing highlights a company building the kind of technology that changes how entire industries get work done. CEO Puneet Puri, CTO Vishal Dugar, and the Gritt team secured backing from Obvious Ventures, with participation from Union Square Ventures, Active Impact Investments, and the broader investor group. The round reflects growing confidence in a company tackling one of infrastructure's biggest operational challenges hiding in plain sight.

Infrastructure has never had a shortage of projects. It has a shortage of speed, labor, and certainty. That is where Gritt comes in. Building intelligent robotic systems that automate critical construction workflows is not about replacing people. It is about giving skilled crews the leverage to accomplish what the market is demanding but traditional methods cannot deliver fast enough. When robotics and AI move from polished demos to measurable productivity in the field, that is when real businesses get built.

What stands out is not just the technology. It is the discipline behind it. You do not attract investors like Obvious Ventures and Union Square Ventures by showing cool robots. You earn that confidence by demonstrating execution, solving painful customer problems, and proving the solution creates economic value where it counts. Markets reward outcomes, not prototypes.

The solar and infrastructure sectors are entering an era where labor constraints are not temporary speed bumps. They are strategic realities. Companies that can increase output, improve consistency, and help projects get completed faster are going to become essential partners rather than optional vendors.

For founders, there are a few lessons worth paying attention to. Pick a painful problem customers already spend money trying to solve. Build technology that creates obvious ROI instead of chasing hype cycles. Stay obsessed with execution after the first customer says yes. Capital tends to find companies that remove friction from massive markets.

This funding is not the finish line. It is fuel to expand the platform, accelerate deployment, advance AI-powered robotics, and help modernize an industry that is overdue for a technological upgrade. The $26M raise is more than fresh capital. It is validation that customers are demanding smarter ways to build critical infrastructure, and the market is rewarding companies that deliver measurable results instead of promises.

Assort Health

Assort Health just pulled in $120M in Series C funding led by Menlo Ventures, landing at a $1.2B valuation and pushing total funding past $222M. That is a serious check for a company attacking one of healthcare's least glamorous problems: the administrative mess sitting between patients and care.

Co-CEOs Jon Wang and Jeffery Liu and the Assort Health team secured backing from Menlo Ventures, alongside Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital. The investor syndicate reflects continued conviction that solving painful operational problems creates more durable businesses than chasing the latest trend.

Healthcare has never suffered from a shortage of intelligence. It has suffered from a shortage of time. Every unnecessary transfer, every hold queue, every referral that disappears into administrative limbo steals attention from the people who actually need care. The industry has spent decades treating paperwork like it was part of the treatment plan. Assort Health looked at that reality and decided the patient journey deserved a better memory than a stack of sticky notes and a voicemail box.

That is where this funding gets interesting. Assort Health is building AI agents that manage scheduling, intake, referrals, document processing, medication refills, eligibility checks, payments, and outreach across the patient journey. Underneath it sits a proprietary foundation trained on more than 190M specialty patient interactions, 62,000 care protocols, and 1.6M decision pathways. Those are not vanity metrics. They represent experience at a scale that gives healthcare organizations a chance to replace friction with flow.

The commercial traction deserves attention as well. Revenue has grown 20x in the last 15 months. Customers are seeing a 5% increase in appointment volume, a 115% increase in labor capacity, and stronger patient satisfaction. Those numbers tell a bigger story. AI is graduating from answering questions to quietly handling the operational work that keeps healthcare moving. The loudest technology in the room is rarely the one creating the most value.

This round also reminds founders of a lesson that never goes out of style. Venture capital chases momentum, but momentum is earned. Build where the pain is measurable, prove the outcomes with numbers customers cannot ignore, and investors tend to find your calendar before you find theirs. Markets change. Human frustration does not. The companies that eliminate it usually end up earning the biggest checks.

Alocity

Alocity is one of those company names that starts making more sense the longer you look at what the business actually does. A lot of companies promise smarter buildings. Alocity is focused on making physical spaces think a little faster than the people trying to create problems inside them.

CEO Marco Quintero and the Alocity team closed a Series A funding round led by a private investor group alongside Marco Quintero, with the funding amount undisclosed. Sometimes the loudest number in a funding announcement is the one you never see. Capital follows conviction long before it follows headlines.

Physical security has spent years collecting mountains of video that nobody has time to watch. Cameras became expensive historians instead of active participants. Alocity is attacking that reality by combining AI Operators, embedded AI video intelligence, and existing security infrastructure into a platform designed to help organizations secure, automate, and operate physical spaces without forcing customers into costly rip-and-replace projects.

That matters because technology adoption usually loses momentum the moment someone says, Throw everything out and start over. Businesses rarely want revolutions that require dumpsters. They want evolution that works with what they already own. Retrofitting existing cameras and access control infrastructure while layering in AI is a far more practical path to enterprise adoption.

The Series A investment is expected to accelerate product innovation, expand engineering, customer success, sales, and marketing, strengthen strategic technology partnerships, and continue scaling Alocity's network of security integration partners. Investors are not simply funding software. They are backing the infrastructure required to move AI deeper into the physical world, where decisions happen in seconds, not slide decks.

There is another lesson hiding in the announcement. Awards, product execution, customer relevance, and solving expensive problems create momentum that investors recognize. Great fundraising stories rarely begin in the boardroom. They begin years earlier by building something customers actually need.

Watching AI move beyond screens and into the environments where people work, learn, heal, and live is becoming one of the most interesting stories in technology. Alocity just added another chapter worth paying attention to. That is the part worth watching.

Sofab Inks

Sofab Inks just raised $6M in seed funding led by Cloudberry Ventures, and the financing highlights one of the less visible challenges standing between promising solar technology and commercial reality.

The company is building TinFab, a metal-oxide electron transport layer designed to replace C60 in perovskite solar cells. That sounds deeply technical because it is. But the business point is simple. If perovskite solar technology is going to move from impressive lab performance to reliable commercial manufacturing, the materials inside the cell stack have to become more durable, more scalable, and more economical. That is the lane Sofab Inks is trying to own.

CEO Blake Martin, Ph.D., COO Jack Manzella, MBA, Lead Engineer Peter Armstrong, Ph.D., Lead Chemist Sashil Chapagain, and the Sofab Inks team secured backing from Cloudberry Ventures to advance technology that must withstand relentless scientific scrutiny before it ever reaches commercial scale.

The company emerged from University of Louisville research, earned recognition through the U.S. Department of Energy's American-Made Perovskite Startup Prize, closed an oversubscribed $1.2M pre-seed round, and has now progressed to a $6M seed round with customer validation already part of the story.

That progression matters. Climate tech does not reward theater forever. Eventually, the market asks whether the product can survive manufacturing reality. Sofab Inks is answering that question through efficiency validation, module performance, production scale-up work, and a roadmap toward commercial 1-by-2-meter modules.

Customer-validated efficiencies reaching 24% in PIN architectures, 25% in NIP architectures, and more than 30% in tandem architectures show why manufacturers are paying attention. The bigger signal is not only the efficiency numbers. It is the combination of performance, durability, scalability, and cost moving in the same direction.

The lesson for founders is not to build in climate. It is to understand the customer problem so precisely that solving it makes an entire category easier to adopt. The lesson for investors is similar. Deep tech rarely rewards impatience. Commercialization takes time, scientific credibility has to be earned, and trust compounds more slowly than software metrics. But when the underlying technology works, entire industries notice.

Woddle Baby

Woddle Baby raised $5M in seed funding led by Capital Q Ventures, and the interesting part is not just the check. It is the shape of the problem. Parenting is one of the biggest data gaps in daily life. A newborn can turn a quiet room into a command center at 2:00 a.m., and most parents are left translating cries, temperature checks, weight changes, and gut instinct into decisions they hope are right. Woddle Baby is building for that moment.

Founded by CEO Shaker Rawan and CTO Steven Holmes, with Dr. Anand Rajani serving as Chief Medical Advisor, the company is developing an AI-powered infant health monitoring platform centered on a smart changing pad. The product captures clinical-grade biometric data during a routine parents already perform throughout the day: diaper changes. That is the product insight. Do not create another habit. Improve one that already exists.

The bigger business signal is where Woddle Baby is heading next. This is not only a consumer baby device story. The company is moving toward clinical remote patient monitoring, connecting families, providers, health systems, and payers around continuous infant health intelligence. That turns a nursery product into something closer to healthcare infrastructure.

That matters because infant care is not a casual software category. Parents do not need another noisy feed, clinicians do not need another disconnected consumer gadget, and payers do not need another wellness claim with no clinical pathway. The bar is trust, reimbursement, workflow fit, and daily use. For founders, there is a useful lesson here. The strongest healthcare startups often solve for multiple stakeholders at once. Parents want confidence. Clinicians want better visibility between visits. Health systems want earlier signals. Payers want interventions that can reduce downstream costs. When one platform can speak to all of those needs, the market gets more interesting.

Capital Q Ventures' backing of Woddle Baby reflects conviction in that shift. Pediatric digital health is moving from occasional checkups and anxious searches toward continuous, contextual monitoring at home. The company, its leadership team, and Capital Q Ventures are building in a category where technology has to be useful, trusted, and almost invisible. That is a high bar, but it is also where durable healthcare products are built.

Infinity

Infinity just put a $15M seed round behind one of AI infrastructure's least glamorous problems: making new chips useful before the market moves on. That is the part of the AI stack most people skip over. Everyone wants to talk about faster silicon, bigger models, and the next GPU alternative. Fair. Those things matter. But hardware does not become production infrastructure because the spec sheet looks impressive. It becomes production infrastructure when the software layer is mature enough for real workloads. That is the opening Infinity is chasing.

Founded by Jeremy Nixon, former Google Brain researcher and AGI House co-founder, Infinity is building Ignition, an autonomous AI research agent that generates, tests, and optimizes inference software for new AI chips. The pitch is simple and effective: take work that can require months or years of rare systems engineering talent and compress it into days.

In its work with d-Matrix and the Corsair accelerator, Infinity says Ignition reached up to 92% of theoretical peak performance within 10 hours of first hardware access. The company also says the system brought frontier models like Qwen3, Qwen3.5, and Gemma4 to production-quality inference within 10 days using software generated from scratch. That is not a cute demo. It is the kind of technical proof that makes infrastructure investors lean forward.

That is why this round carries a sharper signal than the usual AI funding headline. Touring Capital, Principal Venture Partners, and a group of OpenAI and Anthropic researchers backed the company, reflecting conviction in the software layer that determines whether expensive hardware becomes adopted infrastructure or just another impressive benchmark with nowhere useful to go.

The reason this matters is bigger than one seed announcement. AI inference is becoming the operating load of the AI economy. Training gets the stadium lights, but inference is where the bill keeps arriving. Every product response, customer workflow, enterprise agent, search summary, and model-powered interface depends on inference running efficiently at scale.

If only a handful of hardware ecosystems can support that workload cleanly, the market stays narrow. If software can help new chips become inference-ready faster, the market becomes more competitive, more flexible, and a lot more interesting.

American Growth Insurance

American Growth Insurance launched with nearly $70M in committed equity funding, backed by Rockbridge Growth Equity and Atomic. Insurance has always been built on trust. The paperwork? That is another story. The financing represents more than another insurance brokerage expansion. CEO Brian Morgan, Co-Founder, Advisor, and Board Member Luke Sophinos, and the American Growth Insurance team are building around a different premise.

This is not about replacing brokers with AI. That is the lazy headline. The smarter conversation is about removing the administrative gravity weighing down great brokers. Every industry has work that creates value and work that simply creates more work. Insurance has accumulated plenty of the latter.

American Growth Insurance is acquiring independent agencies across the United States and rebuilding them around an AI-first operating system while keeping the human relationship exactly where it belongs: with the client. Technology does not earn trust. People do. Technology should simply stop getting in their way.

The company says its pilot across 10 partner agencies delivered roughly a 50% average increase in profits through stronger productivity and revenue growth. Those numbers are worth watching, especially in an industry wrestling with legacy systems, rising operational costs, and an experienced workforce moving closer to retirement. When nearly every AI conversation lands on replacing people, American Growth Insurance is asking a better question: What if AI makes experienced professionals dramatically better instead?

Rockbridge Growth Equity and Atomic are backing a strategy that is not chasing theater. They are investing in one of the largest, most established industries in America and applying modern infrastructure where operational friction has quietly become accepted as normal.

There is another lesson founders should notice. Capital usually follows conviction that has already been tested. Fundraising becomes a different conversation when execution walks into the room before the pitch deck does.

Growth is in the company name, but the real story may be multiplying capability without multiplying complexity. That is a more durable competitive advantage than adding AI language to an old operating model. Insurance has been waiting for meaningful operational innovation. Now we get to see what happens when experienced operators finally have technology working alongside them instead of asking them to work around it.